Cobalt protoporphyrin IX increases endogenous G-CSF and mobilizes HSC and granulocytes to the blood.
Agata SzadeKrzysztof SzadeWitold Norbert NowakKarolina Bukowska-StrakovaLucie MuchovaMonika GońkaMonika ŻukowskaMaciej CieslaNeli Kachamakova-TrojanowskaMarzena Rams-BaronAlicja RatusznaJozef DulakAlicja JózkowiczPublished in: EMBO molecular medicine (2019)
Granulocyte colony-stimulating factor (G-CSF) is used in clinical practice to mobilize cells from the bone marrow to the blood; however, it is not always effective. We show that cobalt protoporphyrin IX (CoPP) increases plasma concentrations of G-CSF, IL-6, and MCP-1 in mice, triggering the mobilization of granulocytes and hematopoietic stem and progenitor cells (HSPC). Compared with recombinant G-CSF, CoPP mobilizes higher number of HSPC and mature granulocytes. In contrast to G-CSF, CoPP does not increase the number of circulating T cells. Transplantation of CoPP-mobilized peripheral blood mononuclear cells (PBMC) results in higher chimerism and faster hematopoietic reconstitution than transplantation of PBMC mobilized by G-CSF. Although CoPP is used to activate Nrf2/HO-1 axis, the observed effects are Nrf2/HO-1 independent. Concluding, CoPP increases expression of mobilization-related cytokines and has superior mobilizing efficiency compared with recombinant G-CSF. This observation could lead to the development of new strategies for the treatment of neutropenia and HSPC transplantation.
Keyphrases
- bone marrow
- clinical practice
- oxidative stress
- mesenchymal stem cells
- magnetic resonance
- cell therapy
- computed tomography
- magnetic resonance imaging
- metabolic syndrome
- pi k akt
- stem cells
- acute lymphoblastic leukemia
- cell free
- insulin resistance
- acute myeloid leukemia
- binding protein
- signaling pathway
- long non coding rna
- gold nanoparticles
- combination therapy
- recombinant human
- chemotherapy induced